-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-8780 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8780 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-8780 in B-Cell Non-Hodgkin Lymphoma Drug Details: JNJ-8780 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B La in Hepatitis C
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ropeginterferon Alfa-2B La in Hepatitis CDrug Details: Ropeginterferon alpha-2b (Besremi) is a long acting interferon. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Dermatomyositis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Dermatomyositis Drug Details: Ravulizumab (Ultomiris) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vudalimab in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Gallbladder Cancer Drug Details: XmAb-717 is under development for the...
-
Product Insights
Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness, and inability to think clearly. The renal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ropeginterferon alfa-2b LA
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ropeginterferon alfa-2b LA Drug Details Ropeginterferon alpha-2b (Besremi) is a long acting interferon. It...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation, and chemotherapy. The CML pipeline drugs market research report provides...
-
Product Insights
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Acute lymphocytic leukemia (ALL) is a cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections, and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain, and breathing problems. Treatment includes chemotherapy, transfusions, transplant, and medications. The ALL pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain. The Hepatitis B pipeline market research report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Essential Thrombocythemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
In essential thrombocythemia, there is mainly an overproduction of platelet-forming cells in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech, and transient ischemic attacks. The Essential Thrombocythemia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Essential Thrombocythemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers...